IPSOGEN has announced that it has signed an agreement with DNAVision, a provider of pharmacogenomic services in Europe. With this agreement, IPSOGEN gains the capability to offer its portfolio of breast cancer profiling tests to institutions and patients in a CLIA/ISO17025 certified environment.
“This agreement with DNAVision, a recognized provider of high quality pharmacogenomic tests enables IPSOGEN to launch a new generation of IVD profiling diagnostic products addressing unmet needs in guiding breast cancer therapies” said Vincent Fert, president and CEO of IPSOGEN.
“DNAVision microarray testing facilities have the most advanced quality standards in Europe. IPSOGEN can now offer its microarray profiling services at the level of quality of quantitative PCR, the industry gold standard. This agreement definitely positions IPSOGEN as a technology leader in diagnostic gene profiling” added Jean-Marc Le Doussal, IPSOGEN Director of Breast Cancer Program.
“We are delighted to combine our quality gene expression services with the genomic signatures discovered and validated by IPSOGEN. With this agreement, we enter in a new era where microarrays are used as diagnostic tools” said Jean-Pol Detiffe, CEO of DNAVision.
“This agreement is a new evidence that DNAVision becomes the technical partner of choice for biotech companies who want to step into the diagnostic market without facing long IVD application procedures but with the help a quality certified service provider generating data available for clinical and diagnostic purposes.” added Michael Herman, DNAVision, Business Development Director.